Delivery Order SPE2DB25D3012-SPE2DB25FXAAA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $1,167.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 ml auto-injector units, with a completion date of September 15, 2025. This non-set-aside competitive award represents a single delivery order transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency (DLA) awarded a $1,365.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector pharmaceutical supplies. This non-set-aside award, issued on August 25, 2025, with completion targeted for August 26, 2025, represents a single delivery transaction under AmerisourceBergen's existing DLA contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $2,672.91 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector units, with performance conducted at the company's Corporate Office location in Conshohocken, Pennsylvania. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, and utilized no set-aside designation, indicating competitive award selection. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of September 15, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the vendor performing the work at its corporate office location in the same municipality. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a $1,751.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies on September 2, 2025, with completion targeted for September 3, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle active through December...
- The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $1,270.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,062.43 to AmerisourceBergen Drug Corp for the supply of XYOSTED 50 mg/0.5 ml auto-injector units. The contract is a firm fixed price delivery order with an ultimate completion date of August 22, 2025, awarded on August 21, 2025, with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector units valued at $1,304.29 under a firm fixed price contract. This non-set-aside delivery order, which is scheduled for completion by September 5, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXAAADelivery Order
The Defense Logistics Agency awarded a $1,306.21 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 MG/0.5 ML auto-injector vials on September 12, 2025, with completion by September 15, 2025. This non-set-aside competitive award represents a pharmaceutical supply delivery executed under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order supports the Defense Logistics Agency's medical supply chain operations serving military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a comprehensive range of pharmaceutical products and medical devices across multiple therapeutic domains through its DLA prime vendor contract. The XYOSTED auto-injector procurement exemplifies the company's role in providing specialized pharmaceutical commodities to support military healthcare programs, complementing its broader portfolio of brand-name and generic medications, vaccines, and medical supplies delivered through firm fixed-price delivery orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/12/25 |